Compare NMFC & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMFC | IRWD |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.2M | 663.6M |
| IPO Year | N/A | 2009 |
| Metric | NMFC | IRWD |
|---|---|---|
| Price | $7.16 | $3.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $8.63 | $7.67 |
| AVG Volume (30 Days) | 480.0K | ★ 2.0M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 15.27% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ $12.51 | $14.73 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $7.29 | $0.66 |
| 52 Week High | $10.90 | $5.78 |
| Indicator | NMFC | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 26.88 | 48.48 |
| Support Level | N/A | $3.08 |
| Resistance Level | $8.17 | $3.95 |
| Average True Range (ATR) | 0.19 | 0.19 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 4.28 | 67.44 |
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.